{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:29:51Z","timestamp":1793982591749,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Adults with attention-deficit hyperactivity disorder (ADHD) often cycle through multiple treatments for reasons that are not well documented. This study analyzed the reasons underlying treatment changes among adults treated for ADHD in a real-world setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were collected via an online reporting form completed by eligible physicians between October and November 2020. Data for adult patients in the United States who were diagnosed with ADHD and initiated a treatment regimen within 1 to 5\u00a0years of chart abstraction were obtained. Reason for a treatment change was described for a randomly selected regimen episode, which spanned from treatment initiation until the earliest among treatment add-on\/switch or discontinuation, death, or date of chart abstraction. The overall rate of ADHD\/treatment-related complications were also described. Physician satisfaction with current treatment options for adult ADHD and opinions on areas for improvement were assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data on 320 patients were reported by 152 physicians specializing in psychiatry (40.1%), pediatrics (25.0%), family medicine (21.7%), and internal medicine (13.2%). Patients had a mean age of 29.3\u00a0years; most were diagnosed with ADHD as adults (57.5%) and within the previous 5\u00a0years (56.5%). Selected treatment regimens included stimulants (79.1%), nonstimulants (14.7%), and combination therapy (5.6%) for an average duration of 1.9\u00a0years. Among patients with treatment discontinuation (<jats:italic>N\u2009<\/jats:italic>=\u200959), the most common reasons for discontinuation were suboptimal symptom management (55.9%), occurrence of ADHD\/treatment-related complications (25.4%), and patient attitude\/dislike of medication (25.4%). The main reasons for other key treatment changes were inadequate\/suboptimal management of symptoms and cost considerations. Over 40% of patients had\u2009\u2265\u20091 documented ADHD\/treatment-related complication, irrespective of whether they led to a treatment change. One in 5 physicians (19.8%) were very dissatisfied, moderately dissatisfied, or neither satisfied nor dissatisfied with current treatment options for ADHD in adults; the top 3 suggested improvements were lower risk of abuse (71.7%), longer effect duration (65.1%), and fewer ADHD\/treatment-related complications (61.2%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The top reasons for treatment changes among adults with ADHD are lack of efficacy and ADHD\/treatment-related complications, highlighting the importance of developing more effective and safer treatments to alleviate the burden of ADHD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-022-04016-9","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T10:03:45Z","timestamp":1654250625000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Reasons for treatment changes in adults with attention-deficit\/hyperactivity disorder: a\u00a0chart review study"],"prefix":"10.1186","volume":"22","author":[{"given":"Jeff","family":"Schein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Childress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Cloutier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvi","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andi","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Simes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"issue":"1","key":"4016_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.encep.2019.06.005","volume":"46","author":"S Weibel","year":"2020","unstructured":"Weibel S, Menard O, Ionita A, Boumendjel M, Cabelguen C, Kraemer C, et al. Practical considerations for the evaluation and management of attention deficit hyperactivity disorder (ADHD) in adults. Encephale. 2020;46(1):30\u201340.","journal-title":"Encephale"},{"issue":"5","key":"4016_CR2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2217\/npy.13.59","volume":"3","author":"JN Epstein","year":"2013","unstructured":"Epstein JN, Loren RE. Changes in the definition of ADHD in DSM-5: subtle but important. Neuropsychiatry (London). 2013;3(5):455\u20138.","journal-title":"Neuropsychiatry (London)"},{"issue":"4","key":"4016_CR3","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1176\/ajp.2006.163.4.716","volume":"163","author":"RC Kessler","year":"2006","unstructured":"Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716\u201323.","journal-title":"Am J Psychiatry"},{"issue":"11","key":"4016_CR4","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/archinte.164.11.1221","volume":"164","author":"SV Faraone","year":"2004","unstructured":"Faraone SV, Spencer TJ, Montano CB, Biederman J. Attention-deficit\/hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care. Arch Intern Med. 2004;164(11):1221\u20136.","journal-title":"Arch Intern Med"},{"issue":"5\u20136","key":"4016_CR5","first-page":"10","volume":"9","author":"R Agarwal","year":"2012","unstructured":"Agarwal R, Goldenberg M, Perry R, IsHak WW. The quality of life of adults with attention deficit hyperactivity disorder: a systematic review. Innov Clin Neurosci. 2012;9(5\u20136):10\u201321.","journal-title":"Innov Clin Neurosci"},{"issue":"9","key":"4016_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1177\/1087054717733046","volume":"23","author":"J Quintero","year":"2019","unstructured":"Quintero J, Morales I, Vera R, Zuluaga P, Fernandez A. The impact of adult ADHD in the quality of life profile. J Atten Disord. 2019;23(9):1007\u201316.","journal-title":"J Atten Disord"},{"issue":"3","key":"4016_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41380-018-0116-3","volume":"24","author":"A Caye","year":"2019","unstructured":"Caye A, Swanson JM, Coghill D, Rohde LA. Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol Psychiatry. 2019;24(3):390\u2013408.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"4016_CR8","doi-asserted-by":"publisher","first-page":"e019700","DOI":"10.1136\/bmjopen-2017-019700","volume":"8","author":"E Anker","year":"2018","unstructured":"Anker E, Bendiksen B, Heir T. Comorbid psychiatric disorders in a clinical sample of adults with ADHD, and associations with education, work and social characteristics: a cross-sectional study. BMJ Open. 2018;8(3):e019700.","journal-title":"BMJ Open"},{"issue":"6","key":"4016_CR9","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1177\/0004867415609423","volume":"50","author":"YJ Lin","year":"2016","unstructured":"Lin YJ, Yang LK, Gau SS. Psychiatric comorbidities of adults with early- and late-onset attention-deficit\/hyperactivity disorder. Aust N Z J Psychiatry. 2016;50(6):548\u201356.","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"4016_CR10","doi-asserted-by":"publisher","first-page":"e0211873","DOI":"10.1371\/journal.pone.0211873","volume":"14","author":"FJ Tsai","year":"2019","unstructured":"Tsai FJ, Tseng WL, Yang LK, Gau SS. Psychiatric comorbid patterns in adults with attention-deficit hyperactivity disorder: treatment effect and subtypes. PLoS ONE. 2019;14(2):e0211873.","journal-title":"PLoS ONE"},{"issue":"9\u201310","key":"4016_CR11","first-page":"11","volume":"16","author":"T Ohnishi","year":"2019","unstructured":"Ohnishi T, Kobayashi H, Yajima T, Koyama T, Noguchi K. Psychiatric comorbidities in adult attention-deficit\/hyperactivity disorder: prevalence and patterns in the routine clinical setting. Innov Clin Neurosci. 2019;16(9\u201310):11\u20136.","journal-title":"Innov Clin Neurosci"},{"issue":"9","key":"4016_CR12","doi-asserted-by":"publisher","first-page":"e0204516","DOI":"10.1371\/journal.pone.0204516","volume":"13","author":"Q Chen","year":"2018","unstructured":"Chen Q, Hartman CA, Haavik J, Harro J, Klungsoyr K, Hegvik TA, et al. Common psychiatric and metabolic comorbidity of adult attention-deficit\/hyperactivity disorder: a population-based cross-sectional study. PLoS ONE. 2018;13(9):e0204516.","journal-title":"PLoS ONE"},{"issue":"9","key":"4016_CR13","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2215-0366(21)00171-1","volume":"8","author":"E Du Rietz","year":"2021","unstructured":"Du Rietz E, Brikell I, Butwicka A, Leone M, Chang Z, Cortese S, et al. Mapping phenotypic and aetiological associations between ADHD and physical conditions in adulthood in Sweden: a genetically informed register study. Lancet Psychiatry. 2021;8(9):774\u201383.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"4016_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/1087054716669589","volume":"22","author":"JT Instanes","year":"2018","unstructured":"Instanes JT, Klungsoyr K, Halmoy A, Fasmer OB, Haavik J. Adult ADHD and comorbid somatic disease: a systematic literature review. J Atten Disord. 2018;22(3):203\u201328.","journal-title":"J Atten Disord"},{"issue":"4","key":"4016_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s40273-020-00998-0","volume":"39","author":"A Chhibber","year":"2021","unstructured":"Chhibber A, Watanabe AH, Chaisai C, Veettil SK, Chaiyakunapruk N. Global economic burden of attention-deficit\/hyperactivity disorder: a systematic review. Pharmacoeconomics. 2021;39(4):399\u2013420.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"4016_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/oem.2007.038448","volume":"65","author":"R de Graaf","year":"2008","unstructured":"de Graaf R, Kessler RC, Fayyad J, ten Have M, Alonso J, Angermeyer M, et al. The prevalence and effects of adult attention-deficit\/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO world mental health survey initiative. Occup Environ Med. 2008;65(12):835\u201342.","journal-title":"Occup Environ Med"},{"issue":"3","key":"4016_CR17","doi-asserted-by":"publisher","first-page":"e0247724","DOI":"10.1371\/journal.pone.0247724","volume":"16","author":"A Jangmo","year":"2021","unstructured":"Jangmo A, Kuja-Halkola R, Perez-Vigil A, Almqvist C, Bulik CM, D\u2019Onofrio B, et al. Attention-deficit\/hyperactivity disorder and occupational outcomes: the role of educational attainment, comorbid developmental disorders, and intellectual disability. PLoS ONE. 2021;16(3):e0247724.","journal-title":"PLoS ONE"},{"issue":"Supplement 1","key":"4016_CR18","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.1016\/j.jval.2021.04.626","volume":"24","author":"LA Adler","year":"2021","unstructured":"Adler LA, Childress A, Cloutier M, Gagnon-Sanschagrin P, Davidson M, Kinkead F, et al. PMH4 economic burden of attention-deficit\/hyperactivity disorder (ADHD) among adults in the United States: a societal perspective. Value in Health. 2021;24(Supplement 1):S128.","journal-title":"Value in Health"},{"issue":"3","key":"4016_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1001\/jamapsychiatry.2013.4174","volume":"71","author":"Z Chang","year":"2014","unstructured":"Chang Z, Lichtenstein P, D\u2019Onofrio BM, Sjolander A, Larsson H. Serious transport accidents in adults with attention-deficit\/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiat. 2014;71(3):319\u201325.","journal-title":"JAMA Psychiat"},{"issue":"8","key":"4016_CR20","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/jcpp.12164","volume":"55","author":"Z Chang","year":"2014","unstructured":"Chang Z, Lichtenstein P, Halldner L, D\u2019Onofrio B, Serlachius E, Fazel S, et al. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 2014;55(8):878\u201385.","journal-title":"J Child Psychol Psychiatry"},{"issue":"21","key":"4016_CR21","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1203241","volume":"367","author":"P Lichtenstein","year":"2012","unstructured":"Lichtenstein P, Halldner L, Zetterqvist J, Sjolander A, Serlachius E, Fazel S, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012;367(21):2006\u201314.","journal-title":"N Engl J Med"},{"issue":"12","key":"4016_CR22","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1080\/14656566.2019.1618270","volume":"20","author":"G Perugi","year":"2019","unstructured":"Perugi G, Pallucchini A, Rizzato S, Pinzone V, De Rossi P. Current and emerging pharmacotherapy for the treatment of adult attention deficit hyperactivity disorder (ADHD). Expert Opin Pharmacother. 2019;20(12):1457\u201370.","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"4016_CR23","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1007\/s00213-020-05576-y","volume":"237","author":"J Biederman","year":"2020","unstructured":"Biederman J, Fried R, DiSalvo M, Woodworth KY, Biederman I, Driscoll H, et al. Further evidence of low adherence to stimulant treatment in adult ADHD: an electronic medical record study examining timely renewal of a stimulant prescription. Psychopharmacology. 2020;237(9):2835\u201343.","journal-title":"Psychopharmacology"},{"issue":"5","key":"4016_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eurpsy.2012.01.002","volume":"27","author":"H Caisley","year":"2012","unstructured":"Caisley H, Muller U. Adherence to medication in adults with attention deficit hyperactivity disorder and pro re nata dosing of psychostimulants: a systematic review. Eur Psychiatry. 2012;27(5):343\u20139.","journal-title":"Eur Psychiatry"},{"issue":"7","key":"4016_CR25","doi-asserted-by":"publisher","first-page":"570","DOI":"10.18553\/jmcp.2007.13.7.570","volume":"13","author":"M Olfson","year":"2007","unstructured":"Olfson M, Marcus SC, Zhang HF, Wan GJ. Continuity in methylphenidate treatment of adults with attention-deficit\/hyperactivity disorder. J Manag Care Pharm. 2007;13(7):570\u20137.","journal-title":"J Manag Care Pharm"},{"key":"4016_CR26","doi-asserted-by":"crossref","unstructured":"Schein J, Childress A, Adams J, Cloutier M, Gagnon-Sanschagrin P, Maitland J, et al. Treatment patterns among adults with attention-deficit\/hyperactivity disorder in the United States: a retrospective claims study. Curr Med Res Opin.\u00a02021;37(11):2007\u20132014.","DOI":"10.1080\/03007995.2021.1968814"},{"key":"4016_CR27","first-page":"1543","volume":"10","author":"K Gajria","year":"2014","unstructured":"Gajria K, Lu M, Sikirica V, Greven P, Zhong Y, Qin P, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit\/hyperactivity disorder - a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543\u201369.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"4016_CR28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.18553\/jmcp.2004.10.2.122","volume":"10","author":"A Perwien","year":"2004","unstructured":"Perwien A, Hall J, Swensen A, Swindle R. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit\/hyperactivity disorder. J Manag Care Pharm. 2004;10(2):122\u20139.","journal-title":"J Manag Care Pharm"},{"issue":"8 Spec No.","key":"4016_CR29","first-page":"SP329","volume":"24","author":"Z Zhou","year":"2018","unstructured":"Zhou Z, Zhou ZY, Kellar SS, Sikirica V, Xie J, Grebla R. Treatment patterns among adults with ADHD receiving long-acting therapy. Am J Manag Care. 2018;24(8 Spec No.):SP329\u201337.","journal-title":"Am J Manag Care"},{"issue":"5","key":"4016_CR30","doi-asserted-by":"publisher","first-page":"e194980","DOI":"10.1001\/jamanetworkopen.2019.4980","volume":"2","author":"AP Lam","year":"2019","unstructured":"Lam AP, Matthies S, Graf E, Colla M, Jacob C, Sobanski E, et al. Long-term effects of multimodal treatment on adult attention-deficit\/hyperactivity disorder symptoms: follow-up analysis of the COMPAS trial. JAMA Netw Open. 2019;2(5):e194980.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"4016_CR31","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/00325481.2019.1647080","volume":"131","author":"LA Adler","year":"2019","unstructured":"Adler LA, Farahbakhshian S, Romero B, Flood E, Doll H. Healthcare provider perspectives on diagnosing and treating adults with attention-deficit\/hyperactivity disorder. Postgrad Med. 2019;131(7):461\u201372.","journal-title":"Postgrad Med"},{"issue":"Suppl 2","key":"4016_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1185\/03007995.2011.623158","volume":"27","author":"P Hodgkins","year":"2011","unstructured":"Hodgkins P, Sasane R, Christensen L, Harley C, Liu F. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. Curr Med Res Opin. 2011;27(Suppl 2):53\u201362.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"4016_CR33","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1586\/14737175.2016.1135735","volume":"16","author":"M Buoli","year":"2016","unstructured":"Buoli M, Serati M, Cahn W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev Neurother. 2016;16(2):131\u201344.","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"4016_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jsmc.2017.03.011","volume":"12","author":"JF Pagel","year":"2017","unstructured":"Pagel JF. Drug-induced hypersomnolence. Sleep Med Clin. 2017;12(3):383\u201393.","journal-title":"Sleep Med Clin"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04016-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-022-04016-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-04016-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T10:20:44Z","timestamp":1654251644000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-022-04016-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4016"],"URL":"https:\/\/doi.org\/10.1186\/s12888-022-04016-9","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"3 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the applicable ethical regulations and was approved (with exemption from full review) by the Western Institutional Review Board\u2013Copernicus Group Institutional Review Board. The Institutional Review Board further waived informed consent requirement as the data collected did not include any patient-identifying information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ann Childress received research support from Adlon, Allergan, Axial, Takeda\/Shire, Emalex, Akili, Arbor, Neos Therapeutics, Otsuka, Pfizer, Purdue, Rhodes, Sunovion, Tris, KemPharm, Supernus, and the U.S. Food and Drug Administration; was on the advisory board of Takeda\/Shire, Akili, Arbor, Cingulate, Ironshore, Neos Therapeutics, Otsuka, Pfizer, Purdue, Adlon, Rhodes, Sunovion, Tris, Supernus, Noven, and Corium; received consulting fees from Arbor, Ironshore, Lumos, Neos Therapeutics, Purdue, Rhodes, Sunovion, Tris, KemPharm, Supernus, Corium, Jazz, and Tulex Pharma; received speaker fees from Takeda\/Shire, Arbor, Ironshore, Neos Therapeutics, Pfizer, Tris, and Supernus; and received writing support from Takeda \/Shire, Arbor, Ironshore, Neos Therapeutics, Pfizer, Purdue, Rhodes, Sunovion, and Tris. Annie Guerin, Martin Cloutier, Urvi Desai, and Andi Chin are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Otsuka Pharmaceutical Development & Commercialization, Inc., which funded the development and conduct of this study and manuscript. Mark Simes was an employee of Analysis Group, Inc. at the time of the study. Jeff Schein is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. Julie Adams was an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. at the time of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"377"}}